Home » Larry Mahan » Biotechnology Innovation Organization’s International Convention

Biotechnology Innovation Organization’s International Convention

posted in: Conventiion, Larry Mahan 0

LONDON, ONTARIO June 12, 2020 — Dr. Larry Mahan, CEO of OB Pharmaceuticals, attended the
Biotechnology Innovation Organization’s International Convention (June 8-12) in its Digital BIO 2020
format to meet with prospective investors for the company’s capital raise initiative and with key
contract research organizations whose services will be required moving forward. The company is
concluding its preclinical lead development phase for TD567 and will be seeking funding to complete
IND/CTA-enabling GLP toxicology studies prior to filing its IND and CTA to proceed into clinical trials.
These introductory meetings resulted in several follow-on requests by investors.

About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of
individuals through the development of first-in-class therapeutics for more effective prevention and
management of epilepsy and other related seizure disorders.

Leave a Reply

Your email address will not be published. Required fields are marked *